Abstract:Aims: Advances in treatment have extended the life expectancy of patients with metastatic bone disease (MBD). Patients could experience more skeletal-related events (SREs) as a result of this progress. Those who have already experienced a SRE could encounter another local management for a subsequent SRE, which is not part of the treatment for the initial SRE. However, there is a noted gap in research on the rate and characteristics of subsequent SREs requiring further localized treatment, obligating clinicians to extrapolate from experiences with initial SREs when confronting subsequent ones. This study aimed to investigate the proportion of MBD patients developing subsequent SREs requiring local treatment, examine if there are prognostic differences at the initial treatment between those with single versus subsequent SREs, and determine if clinical, oncological, and prognostic features differ between initial and subsequent SRE treatments. Methods: This retrospective study included 3,814 adult patients who received local treatment - surgery and/or radiotherapy - for bone metastasis between 1 January 2010 and 31 December 2019. All included patients had at least one SRE requiring local treatment. A subsequent SRE was defined as a second SRE requiring local treatment. Clinical, oncological, and prognostic features were compared between single SREs and subsequent SREs using Mann-Whitney U test, Fisher's exact test, and Kaplan-Meier curve. Results: Of the 3,814 patients with SREs, 3,159 (83%) patients had a single SRE and 655 (17%) patients developed a subsequent SRE. Patients who developed subsequent SREs generally had characteristics that favoured longer survival, such as higher BMI, higher albumin levels, fewer comorbidities, or lower neutrophil count. Once the patient got to the point of subsequent SRE, their clinical and oncological characteristics and one-year survival (28%) were not as good as those with only a single SRE (35%; p < 0.001), indicating that clinicians' experiences when treating the initial SRE are not similar when treating a subsequent SRE. Conclusion: This study found that 17% of patients required treatments for a second, subsequent SRE, and the current clinical guideline did not provide a specific approach to this clinical condition. We observed that referencing the initial treatment, patients in the subsequent SRE group had longer six-week, 90-day, and one-year median survival than patients in the single SRE group. Once patients develop a subsequent SRE, they have a worse one-year survival rate than those who receive treatment for a single SRE. Future research should identify prognostic factors and assess the applicability of existing survival prediction models for better management of subsequent SREs.

Long-term clinical outcomes after the second metastasectomy in patients with resected metastatic colorectal cancer

[Surgical Outcomes of Second Liver Resections for Recurrent Hepatic Metastases from Colorectal Cancer].

Survival and Prognostic Factors of Colorectal Liver Metastases after Surgical and Nonsurgical Treatment.

Long-Term Outcome After Resection of Hepatic and Pulmonary Metastases in Multivisceral Colorectal Cancer

The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy

Clinical outcomes of patients with metachronous second primary lung adenocarcinomas.

Favourable surgical outcomes for either second primary lung cancer or intrapulmonary metastasis after resection of non-small-cell lung cancer

Surgical treatment of metachronous second primary lung cancer.

Long-Term Outcomes after Surgical Resection for Synchronous or Metachronous Hepatic and Pulmonary Colorectal Cancer Metastases

Clinical effects of second resection on high-risk non-muscle invasive bladder cancer

Long-term oncological outcomes after laparoscopic parenchyma-sparing redo liver resections for patients with metastatic colorectal cancer: a European multi-center study

[Analysis of Long-Term Outcomes and Risk Factors in Patients Undergoing Simultaneous Resection of Synchronous Colorectal Liver Metastasis].

Survival Outcomes and Predictors for Recurrence of Surgically Treated Brain Metastasis From Non-Small Cell Lung Cancer

Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment

Clinical, oncological, and prognostic differences of patients with subsequent skeletal-related events in bone metastases

Second malignancy in advanced or recurrent non‐small cell lung cancer after the advent of molecular targeted drugs and immunotherapy

Efficacy and Safety of a Second Course of Stereotactic Radiation Therapy for Locally Recurrent Brain Metastases: A Systematic Review

Long-term outcomes after endoscopic versus surgical resection of T1 colorectal carcinoma

[Clinicopathological Characteristics and Prognosis of Patients with Recurrent Colorectal Cancer].

[Evaluation of Long-Term Survival after Hepatic Resection for Metastatic Colorectal Cancer-a Multifactorial Model of 191 Patients].

Surgical Resection for Second Primary Colorectal Cancer: a Population-Based Study.